Search research articles
Contact Us
Filters
Showing results (151-160 of 245) with videos related to
Page
of 25
Sort By:
Leukemia & Lymphoma
|
March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica
|
October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
Phuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Blood
|
August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
Steven I Park, Jaideep Shenoi, John M Pagel, et al.
American Journal of Hematology
|
April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma
Victor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 5, 2015
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation
Sofia H L Frost, Brian W Miller, Tom A Bäck, et al.
Plos One
|
March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models
Sofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Johnnie J Orozco, Phuong T Vo, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
Lihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
Anthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Page
of 25
Search research articles
Search
Showing results (151-160 of 245) with videos related to
Sort By:
Page
of 25
Leukemia & Lymphoma
|
March 3, 2015
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E Coutré, Jacqueline C Barrientos, Jennifer R Brown, et al.
Blood
|
September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
John M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica
|
October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
Phuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Blood
|
August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
Steven I Park, Jaideep Shenoi, John M Pagel, et al.
American Journal of Hematology
|
April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma
Victor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 5, 2015
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation
Sofia H L Frost, Brian W Miller, Tom A Bäck, et al.
Plos One
|
March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models
Sofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Johnnie J Orozco, Phuong T Vo, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation
Lihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
Anthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Page
of 25